We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
-7.9%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$1.39B
AUM Growth
-$202M
Cap. Flow
+$27.4M
Cap. Flow %
1.97%
Top 10 Hldgs %
51.89%
Holding
98
New
17
Increased
22
Reduced
21
Closed
23

Top Buys

Rank Stock Value
1
BBNX
Beta Bionics
BBNX
+$63.3M
2
NVCR icon
NovoCure
NVCR
+$63.2M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$56M
4
STAA icon
STAAR Surgical
STAA
+$51.4M
5
HOLX
Hologic
HOLX
+$20M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$29.3M
2
AXGN icon
Axogen
AXGN
+$27.2M
3
AZN icon
AstraZeneca
AZN
+$26.8M
4
QDEL icon
QuidelOrtho
QDEL
+$24.4M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$23.6M

Sector Composition

Rank Sector Weight
1 Healthcare 91.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$114M 8.17%
1,400,000
-1,600,000
-53% -$143M
TGTX icon
2
TG Therapeutics
TGTX
$8.58B
$112M 8.08%
2,846,703
+165,461
+6% +$5.57M
NVCR icon
3
NovoCure
NVCR
$2.04B
$98.4M 7.08%
5,521,414
+2,781,710
+102% +$63.2M
KRYS icon
4
Krystal Biotech
KRYS
$9.88B
$79.6M 5.73%
441,758
+83,379
+23% +$14M
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$11.5B
$76.3M 5.49%
1,079,304
+77,904
+8% +$5.24M
ORGO icon
6
Organogenesis Holdings
ORGO
$308M
$53.9M 3.88%
12,478,351
-6,525
-0.1% -$26.3K
GRFS
7
Grifois
GRFS
$5.16B
$50.4M 3.63%
7,089,822
+484,397
+7% +$3.65M
UTHR icon
8
United Therapeutics
UTHR
$26.3B
$47.9M 3.45%
155,394
+46,000
+42% +$15.8M
STAA icon
9
STAAR Surgical
STAA
$1.16B
$45.2M 3.25%
+2,562,893
New +$51.4M
PRAX icon
10
Praxis Precision Medicines
PRAX
$9.07B
$43.2M 3.11%
1,139,740
+896,200
+368% +$56M
BBNX
11
Beta Bionics
BBNX
$706M
$41.6M 2.99%
+3,395,341
New +$63.3M
NPCE icon
12
Neuropace
NPCE
$505M
$32.1M 2.31%
2,608,168
+175,000
+7% +$2.19M
NRIX icon
13
Nurix Therapeutics
NRIX
$2.43B
$28.8M 2.07%
2,422,833
+320,000
+15% +$5.35M
AXGN icon
14
Axogen
AXGN
$2.1B
$26.8M 1.93%
1,446,117
-1,509,826
-51% -$27.2M
CELC icon
15
Celcuity
CELC
$4.03B
$26M 1.87%
2,574,122
+9,035
+0.4% +$102K
IOVA icon
16
Iovance Biotherapeutics
IOVA
$2.23B
$25.9M 1.87%
7,785,000
+1,225,000
+19% +$6.32M
SRDX
17
DELISTED
Surmodics
SRDX
$24.1M 1.73%
789,060
+395,000
+100% +$13.3M
IART icon
18
Integra LifeSciences
IART
$1.54B
$23.6M 1.7%
1,072,204
-203,796
-16% -$4.79M
TERN
19
DELISTED
Terns Pharmaceuticals
TERN
$22.5M 1.62%
8,167,100
+24,600
+0.3% +$100K
MDGL icon
20
Madrigal Pharmaceuticals
MDGL
$12.6B
$22.4M 1.61%
67,500
+56,600
+519% +$18.6M
INSM icon
21
Insmed
INSM
$23.2B
$20.9M 1.51%
274,272
-46,000
-14% -$3.52M
RIGL icon
22
Rigel Pharmaceuticals
RIGL
$680M
$20.3M 1.46%
1,130,679
– –
HOLX
23
DELISTED
Hologic
HOLX
$18.7M 1.34%
+302,000
New +$20M
ARGX icon
24
argenx
ARGX
$57.4B
$17.1M 1.23%
+28,940
New +$18.3M
MRUS
25
DELISTED
Merus
MRUS
$16.2M 1.17%
385,821
+73,500
+24% +$3.2M
1
2 3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Soleus Capital Management held 98 positions worth $1.39B, down 13% from $1.59B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Soleus Capital Management's Q1 2025 filing shows 17 new, 22 increased, 21 reduced and 23 closed positions. Its largest new stake was Beta Bionics: 3,395,341 shares worth $41.6M. The largest sale was Teva Pharmaceuticals, an estimated $29.3M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 83% a quarter earlier.

  • Soleus Capital Management's largest Q1 2025 buy was Beta Bionics: 3,395,341 shares worth $41.6M.
  • Soleus Capital Management added most to NovoCure in Q1 2025, an estimated $63.2M increase.
  • Soleus Capital Management's biggest Q1 2025 reduction was Teva Pharmaceuticals, cutting an estimated $29.3M.
  • Soleus Capital Management fully exited AstraZeneca in Q1 2025, selling an estimated $26.8M.
  • Soleus Capital Management's ten largest holdings make up 52% of its $1.39B portfolio in Q1 2025.
  • Soleus Capital Management opened 17 new positions and closed 23 in Q1 2025.
  • Soleus Capital Management's portfolio value fell 13% quarter-over-quarter to $1.39B.

Based on Soleus Capital Management's 13F filing for Q1 2025, filed 15 May 2025.